Monday’s Midday Movers: Clovis Oncology (CLVS), Arrowhead Research (ARWR), Splunk (SPLK), Exact Sciences (EXAS), Zogenix (ZGNX)

By Carrie Williams

So far Monday, November 25, NASDAQ is up 2.64% and the S&P is up 0.83%. Here are this morning’s most active stocks: Clovis Oncology (CLVSResearch Report), Arrowhead Research (ARWRResearch Report), Splunk (SPLKResearch Report), Exact Sciences (EXASResearch Report) and Zogenix (ZGNXResearch Report).

Clovis Oncology is up 8.79% in midday trading to $9.90. Shares opened today at $9.10. The company has a 52-week low of $2.93 and a 52-week high of $32.05. On the Street’s front, the average 12-month analyst price target for the stock is $11.42, marking a 25.49% potential upside from current levels. In a report issued on November 19, Evercore ISI analyst Joshua Schimmer downgraded CLVS to Hold, with a price target of $8.00, which implies a downside of 12% from current levels. Separately, on November 8, H.C. Wainwright’s Edward White reiterated a Buy rating on the stock and has a price target of $36.00.

Arrowhead Research is up 7.93% in midday trading to $57.41. Shares opened today at $53.19. The company has a 52-week low of $10.41 and a 52-week high of $59.72. On the Street’s front, the average 12-month analyst price target for the stock is $55.60, marking a 4.53% potential upside from current levels. In a report released today, Robert W. Baird analyst Madhu Kumar upgraded ARWR to Buy, with a price target of $70.00, which represents a potential upside of 32% from where the stock is currently trading. Separately, on November 19, Cantor Fitzgerald’s Elemer Piros maintained a Hold rating on the stock and has a price target of $50.00. In the last 30 days, insiders purchased $65.65K worth of ARWR shares. Over the last 3 months, the insider sentiment on Arrowhead Research has been negative based on 44 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Splunk is up 5.85% in midday trading to $147.81. Shares opened today at $139.64. The company has a 52-week low of $90.08 and a 52-week high of $148.18. On the Street’s front, the average 12-month analyst price target for the stock is $158.56, marking a 13.55% potential upside from current levels. In a report released today, Goldman Sachs analyst Christopher Merwin maintained a Hold rating on SPLK, with a price target of $147.00, which represents a potential upside of 5% from where the stock is currently trading. Separately, on November 22, William Blair’s David Griffin maintained a Buy rating on the stock .

See today’s analyst top recommended stocks >>

Exact Sciences is up 5.75% in midday trading to $82.71. Shares opened today at $78.21. The company has a 52-week low of $53.06 and a 52-week high of $123.99. On the Street’s front, the average 12-month analyst price target for the stock is $124.73, marking a 59.48% potential upside from current levels. In a report issued on November 15, Stifel Nicolaus analyst Daniel Arias initiated coverage with a Buy rating on EXAS and a price target of $110.00, which implies an upside of 41% from current levels.

See today’s analyst top recommended stocks >>

Zogenix is up 5.4% in midday trading to $50.59. Shares opened today at $48.00. The company has a 52-week low of $33.43 and a 52-week high of $56.50. On the Street’s front, the average 12-month analyst price target for the stock is $63.71, marking a 32.73% potential upside from current levels. In a report released today, Needham analyst Serge Belanger maintained a Buy rating on ZGNX, with a price target of $58.00, which represents a potential upside of 21% from where the stock is currently trading.

Trending Stocks Based on Insider Activity >>